Letters

Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation

Please note: Financial support for this study was provided by Boehringer Ingelheim. The study sponsor had no role in the collection, analysis, and interpretation of data and approved the final version of the manuscript. Dr. Grottke has received research funding from Novo Nordisk, Biotest, CSL Behring, Boehringer Ingelheim and Nycomed; and has received honoraria/travel support for consultancy from Bayer Healthcare, Boehringer Ingelheim, CSL Behring, and Portola. Dr. Honickel has received travel support from Boehringer Ingelheim. Dr. van Ryn is an employee of Boehringer Ingelheim. Dr. ten Cate has received research funding from CSL Behring, Bayer, Philips, Pfizer, and Boehringer Ingelheim; and has received honoraria for lectures and consultancy from Bayer, Leo Pharma, Stago, Boehringer, and Pfizer. Dr. Rossaint has received institutional grant support from Boehringer Ingelheim; and has received honoraria for lectures and consultancy from CSL Behring, Boehringer Ingelheim, and Novo Nordisk. Dr. Spronk has received research funding from Boehringer Ingelheim; and has received honoraria for consultancy from Bayer.